Clinical Efficacy Of CIK Combined With TP Regimen In The Treatment Of Recurrent Ovarian Cancer

Objective: Evaluate the efficacy and safety of cytokine induced killer cells(CIK)combined with paclitaxel and cisplatin(TP)in the treatment of recurrent ovarian cancer,to discuss the relationship between cytokine-induced killer(CIK)cells and chemotherapy.Methods: A retrospective study was performed on the clinical data of 70 recurrent ovarian cancer patients who were admitted to Affiliated Hospital of Zunyi Medical College Department and treated with TP regimen from 2009 to 2016 after failed by surgery and TP chemotherapy,In the 70 patients,35 patients were treated by CIK after chemotherapy(combined treatment group),35 patients only received chemotherapy(chemotherapy group).Chi square test was used to compare the response rate(RR),disease control rate(DCR)and Karnofsky score(KPS).The median progression free survival(median PFS)and the overall survival(OS)were calculated by Kaplan-Meier and Log-rank test..Results: The median follow-up time was 16 months.The RR and DCR of the combined treatment group and the chemotherapy group were 65.7%,88.6%,40.0% and 68.6%,respectively.The combined treatment group was more benefit from RR and DCR than the chemotherapy group(P < 0.05).The median PFS and OS of combined treatment group and chemotherapy group were 8 months(95%CI:7.9-11.1 months),17 months(95%CI:20.9-42.8 months),6 months(95%CI:5.6-8.6 months)and 16 months(95%CI:15.7-28.5months),respectively,compared with chemotherapy group,the median PFS in combination therapy group extended 2 months(P < 0.05).Although compared with the chemotherapy group,the median OS in combined treatment group prolonged 1 month,the difference between the two groups was not statistically significant(P > 0.05).In the quality of life,the combined treatment group was better than chemotherapy group,the decreased percentage of KPS between two groups was statistically significant(P < 0.05),most of patients did not have adverse reaction after infusion,only 1 patient had scalp itching,1patient had body aches,both of them were 1 grade adverse reactions and didn't need special treatment and didn't affect the following treatment.Conclusion: Cytokine-induced killer cells combined with TP chemotherapy in the treatment of recurrent ovarian cancer is safe and effective,and its comprehensive efficacy is better than chemotherapy alone,which has a certain clinical application prospect.